Vizient recently released its Summer 2021 Pharmacy Market Outlook, which projects pharmaceutical spending for 2022 based on an analysis of its members' data. On this episode of Managed Care Cast, we talk about some of the findings.
What’s ahead for hospitals and health systems in projected drug spending for 2022?
Vizient recently released its Summer 2021 Pharmacy Market Outlook, which looks at what purchasers can expect next year. The report, which delves into its members’ purchasing patterns, predicts a 3.1% increase in pharmaceutical spending next year, with oncology drugs accounting for about 25% of the increase. The report also discusses increasing competition from biosimilars, including the recent approval of insulin glargine as an interchangeable biosimilar for the treatment of diabetes; the practice of white bagging; and other issues.
On this episode of Managed Care Cast, we speak with Steven Lucio, PharmD, BCPS, senior principal, Pharmacy Solutions, about the report, which also discusses the continued impact of COVID-19 on health care.
Listen above or through one of these podcast services:
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Robert F. Kennedy Jr Faces Senate Inquiry Over Deep Cuts to HHS Impacting FDA, CDC, NIH, CMS
April 2nd 2025A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear communication regarding their potential impact on American health.
Read More
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More